Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon Sep 07, 2022 11:53pm
84 Views
Post# 34948543

RE:Brokered Private Placement

RE:Brokered Private Placement
Ingiboy wrote:

From Stockwatch: 2022-09-06 16:24 ET - News Release


REPLICEL ANNOUNCES NON-BROKERED PRIVATE PLACEMENT

RepliCel Life Sciences Inc. has arranged a non-brokered private placement financing of up to eight million units at a price of 10 cents per unit for gross proceeds of up to $800,000. Each Unit consists of one common share of the Company (each, a "Share") and one-half of one share purchase warrant (each, a "Warrant"). Each whole Warrant entitles the holder thereof to purchase one additional Share of the Company at a price of $0.20 per Share for a period of three years from closing of the Offering. The Offering is subject to the approval of the TSX Venture Exchange (the "Exchange"). Insiders may participate in the Offering.

Finders' fees may be payable in connection with the Offering in accordance with the policies of the Exchange.

All securities issued in connection with the Offering will be subject to a statutory hold period expiring four months and one day after closing of the Offering. Completion of the Offering is subject to the approval of the Exchange. Any participation by insiders in the Offering will constitute a related party transaction under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101") but is expected to be exempt from the formal valuation and minority shareholder approval requirements of MI 61-101.

The aggregate gross proceeds from the sale of the Offering will be used for general working capital.

Here we go again, running on fumes....need some working capital.  Also another 8,000,000 shares added to the shares issued.  Someone has bucked up $800,000 for some $.10 shares plus warrants.  Can you imagine that last grouip that paid $.18/share plus warrants.  i would feel a bit burned.

o.K. no problem, off we go.  Kick the can down the road for a nother couple of months.  Let's hope we have a happy ending !

 
[/quote


Remember this:
March 21, 2022 – RepliCel Life Sciences Inc. (OTCPK: REPCF) (TSXV: RP) (FRA:P6P2) (“RepliCel” or the “Company”), a company developing novel, next-generation injection technologies as well as regenerative medicine products in aesthetics and orthopedics, is pleased to announce a non-brokered private placement financing (the “Offering”) of up to 8,333,333 units (each, a “Unit”) at a price of $0.18 per Unit for gross proceeds of up to $1,500,000. Each Unit consists of one common share of the Company (each, a “Share”) and one-half of one share purchase warrant (each, a “Warrant”). Each whole Warrant entitles the holder thereof to purchase one additional Share of the Company at a price of $0.40 per Share for a period of three years from closing of the Offering. The Offering is anticipated to close in two tranches, the first tranche to be completed quickly and the second tranche to be completed within ninety (90) days, subject to the approval of the TSX Venture Exchange (the “Exchange”). Insiders may participate in the Offering.

As it turned out they only sold about half of this offering and cancelled the rest. It was to Andrew Schutte if I remember correctly who bought most of the first Tranche.  I am sure he is not impressed that his large pile of shares are watered down once again and this time at $.10.  Or it is just another chance for the insiders including Andrew to average down.  Also it seems evident that the company is running out of working capital as they wait for this Arbitration to conclude.  Good move on Shiseido's part to string this out as long a possible and stress Replicel out financially.

You can bet that those insiders that are offered these shares know much more than we the non insiders about where this Arbitration is headed and what is happening with the Dermal Injector.  For a public company this is atrocious they way they are keeping us completely in the dark. 
<< Previous
Bullboard Posts
Next >>